Hoosiers Work for Health

03/13/2026

The United States leads the world in biotechnology innovation, but that leadership is not guaranteed.

A new article from STAT News highlights concerns that proposals to codify Most Favored Nation drug pricing could discourage investment across the biotech ecosystem. In fact, 26 drugs and 55 research programs have already been discontinued since 2022, raising questions about how policy decisions can shape the future of medical innovation.

For states like Indiana with strong life sciences sectors, these policy choices could affect innovation, research, and high quality jobs. Learn more below.

Health care policy often carries unintended consequences. The Inflation Reduction Act’s “pill penalty,” for example, gave small-molecule drugs — which

03/10/2026

In a new column for Newsmax, health policy expert Sally Pipes warns that “Most Favored Nation” drug pricing could bring foreign government price controls into the U.S.

Many countries use the Quality-Adjusted Life Year to determine whether medicines are worth covering, which can result in patients being denied access to certain treatments.

The piece outlines how tying U.S. drug prices to those systems could have serious implications for patient access and innovation.

Lower foreign prices are not the result of superior bargaining. They are the product of government controls. Canada, the United Kingdom, and much of Europe cap what they are willing to pay for new medicines. If manufacturers refuse, then the drug may not be available to patients.

03/02/2026

Originally designed to help low-income patients, the 340B program has grown enormously. A new study from IQVIA estimates around $1.8 B annually in markups on discounted drugs paid by state health plans. These costs show up in higher premiums and bigger state budgets, raising questions about whether the program is working as intended.

02/25/2026

Last night, during the President’s State of the Union Address, we heard renewed focus on lowering healthcare costs for American families. This is a goal we all share.

However, importing foreign price controls could threaten innovation, limit patient access to new treatments and put Hoosier jobs at risk. Indiana is a life sciences industry leader and policies that weaken investment here will hurt patients and the economy nationally.

Let’s focus on solutions that lower costs and protect innovation, access and jobs in Indiana.

We Work For Health Executive Director Dan Leonard issued the following statement in response to President Trump’s call for the codification of Most Favored Nation price controls during his State of the Union Address. “Last night, we heard again from the Administration about their plans to lower ...

02/24/2026

Maintaining America's momentum demands that policymakers resist policies that undermine research and development incentives.

02/23/2026

Why do U.S. patients often pay more for the same drugs than people in other countries? Part of the answer is a global distortion in pricing. Foreign governments enforce steep price controls, letting their citizens benefit while the U.S. market carries most of the cost of research and development.

Congress should pursue reforms that protect both patients and medical innovation rather than importing policies that could weaken America’s leadership in new cures.

Probably everyone has a friend who is a freeloader — someone who always weasels out of paying their fair share. On a global scale, the United States has a

02/20/2026

The United States has long led the world in medical breakthroughs but patent uncertainty, regulatory pressures and shifting pricing policies could weaken that leadership. Policymakers must ensure the U.S. continues to protect America’s innovation ecosystem so it can keep delivering new treatments for patients everywhere.

The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.

11/18/2025

Indiana employers have tools to hold PBMs accountable and reduce costs. State Rep. Julie McQuire outlines how audits, transparency and legislative action can protect businesses and employees from inflated drug pricing.

Indiana employers have powerful tools at their disposal to fight back, and my colleagues and I have worked hard to pass laws to hold these entities accountable, increase transparency and reduce costs.

11/14/2025

America can either cede the future of biotechnology to our adversaries or summon the vision and resolve to lead it.

10/29/2025

“Indiana is a thriving hub for biotech innovation already.” – Senator Jim Banks, Oct. 29, 2025

We couldn’t agree more. Indiana’s life sciences industry drives discovery in cancer research, regenerative medicine and so much more. With over 3,200 companies, 70,000 Hoosier jobs bringing in $7.4 billion in payroll and over $1.6 billion dollars in research funding annually, Indiana is proud to be a national leader in biotechnology innovation.

Senator Banks’ focus on strengthening FDA processes, ensuring fair inspections abroad, and protecting American intellectual property is critical to supporting future innovation and investment in our state.

09/11/2025

The U.S. can cut drug costs without killing innovation. MFN is a quick fix with big risks like shortages, fewer cures and reduced access. Let’s choose competition and smart reform through strong policy and trade talks instead.

Three months have passed since President Trump signed an executive order on “Delivering Most Favored Nation [MFN] Pricing to American Patients,” which requires that pharma reduce

09/04/2025

Most Favored Nation (MFN) style drug pricing is not innovation friendly. Forcing U.S. pharmaceutical companies to match Europe's low prices risks slower breakthroughs.

Republicans aren’t known for raising hell about prescription drug prices and fighting to keep them as low as possible for consumers. Call it a strength of